Key findings as of August 2026: accelerating test volumes, improving gross margins, multiple analyst target raises, and expanding regulatory milestones.
Facts: NTRA has delivered strong multi-year returns since its July 2015 IPO at $18/share. Historical data shows significant appreciation with notable volatility typical of growth-oriented diagnostics/biotech stocks.
Interpretation: The stock has significantly outperformed broader markets over longer periods, reflecting investor optimism around oncology growth, though short-term movements are sensitive to earnings, regulatory news, and macro factors.
View full historical price data on Macrotrends | Yahoo Finance Historical Quotes
Facts (from company reports and earnings releases):
| Period | Revenue | YoY Growth | Gross Margin | Net Loss (GAAP) | Tests Processed |
|---|---|---|---|---|---|
| Q2 2026 | $752.8M | +37.7% | 64.5% | $67.0M | ~1.044M |
| Q1 2026 | $696.6M | +38.8% | ~64.7% | ~$86M (est.) | ~1.01M |
| Q4 2025 | $665.5M | +39.8% | 66.9% | Improved sequentially | Strong oncology growth |
| Full Year 2025 | $2.306B | +35.9% | 64.7% | $208.2M | ~3.5M |
| Full Year 2024 | $1.697B | +56.8% | 60.3% | $190.4M | N/A |
Interpretation: Revenue growth is primarily driven by higher test volumes (especially oncology/MRD via Signatera) and improving average selling prices. Gross margins have expanded due to scale and cost efficiencies. The company has raised 2026 revenue guidance multiple times (latest: $2.85B–$2.91B). Positive cash flow noted in recent quarters; cash position ~$1.09B as of Q2 2026.
Uncertainties: Path to consistent GAAP profitability remains unclear amid high R&D and SG&A spend. Reimbursement rates, payer coverage expansions, and competition could impact future margins and volumes. Forward-looking statements in earnings releases are subject to risks detailed in SEC filings.
More Information: Official Investor Relations | Yahoo Finance NTRA Page | Macrotrends Revenue History
Facts: Consensus rating is Strong Buy / Buy across major firms. Approximately 17–19 Buy or Strong Buy ratings, 2–3 Hold, and zero Sell ratings based on recent coverage (as of mid-2026 data).
| Metric | Value / Range | Notes |
|---|---|---|
| Consensus Recommendation | Strong Buy / Buy | 19+ analysts tracked |
| Average Price Target | $283 – $315 (range varies by source) | Highs up to $375; Lows ~$193–$249 |
| Recent Activity | Multiple PT raises (e.g., TD Cowen to $325, Canaccord to $330, Morgan Stanley to $310) | Upgrades and new initiations (e.g., Bernstein Buy) |
| Firms Covering | BTIG, Piper Sandler, Guggenheim, Evercore ISI, Wells Fargo, Goldman Sachs, Barclays, etc. | Mostly Buy/Overweight with periodic Hold |
Interpretation: Analysts appear optimistic about Signatera adoption, regulatory progress (Japan approval, IVDR, NCCN recommendations), and overall market expansion in precision medicine. Recent PT increases reflect positive momentum from earnings beats and partnerships.
Uncertainties: Ratings and targets can change rapidly with new clinical data, reimbursement decisions, or macroeconomic shifts. A small number of Hold ratings exist; divergence in targets indicates valuation debates.
More Information: Yahoo Analyst Estimates | MarketBeat Ratings
Facts:
Interpretation: Broad customer base across clinical and research settings supports volume growth; pharma collaborations indicate potential for companion diagnostics.
More Information: Natera Corporate Site | IR Presentations
Facts: No single competitor spans all three focus areas (women’s health, oncology, organ health). Segment-specific rivals include:
| Segment | Key Competitors |
|---|---|
| Women’s Health / NIPT / Carrier Screening | Labcorp, Myriad Genetics, Quest Diagnostics, Illumina (Verinata), BillionToOne, Fulgent Genetics, Revvity |
| Oncology / Liquid Biopsy / MRD | Guardant Health, NeoGenomics, Tempus Labs, Exact Sciences, Personalis |
| Organ Health / Transplant | CareDx (primary) |
Interpretation: Natera’s proprietary cfDNA + bioinformatics/AI platform and large clinical evidence base (400+ publications) provide differentiation, but faces well-established lab giants and emerging precision medicine players.
Uncertainties: New entrants, acquisitions, or technological shifts (e.g., in NGS or AI) could intensify competition. Reimbursement battles common in diagnostics sector.
More Information: Wikipedia Natera | MarketBeat Competitors
This analysis aggregates publicly available information from company filings, earnings releases, news, and financial platforms as of August 2026. It is for informational purposes only and not investment advice. Always conduct your own due diligence and consult professionals. Data subject to change; verify sources directly.
Additional resources: Natera IR • SEC EDGAR • Yahoo Finance